sold all on the very slight bounce, may re-establish a position
Clearly the FDA meeting did not go according to plan with the news of a pivotal BE study...what a shame as there appeared to be ample clinica experience with the PK studies. There is still strong value in Remoxy, but unfortunately it has been significantly delayed for all involved. If PFE indeed decides to continue, it will be reflected in a re-structured deal and eventual in lower pps in ptie/drrx. If PFE abandons, then it will really hit the fan, as the timeline will be further extended and no immediate resources to PTIE. I'll be watching to re-stablish an entry point at much lower pps.